From Zacks Investment Research: 2025-02-14 10:12:08

Alnylam Pharmaceuticals reported fourth-quarter 2024 adjusted earnings of 6 cents per share, beating estimates. Total revenues were $593.2 million, exceeding expectations. Net product revenues were $450.8 million, up 30% year over year. Shares of Alnylam have gained 12.5% in the past three months. The company is collaborating with REGN on cemdisiran and Novartis on PCSK9 therapeutics.

In 2022, the FDA approved Alnylam’s Amvuttra for hATTR amyloidosis. Sales of Onpattro, Givlaari, and Oxlumo were reported. R&D expenses increased 3% while SG&A expenses rose 39% year over year. Cash, cash equivalents, and marketable securities as of Dec. 31, 2024, amounted to $2.69 billion.

For 2024, Alnylam generated total revenues of $2.25 billion and reported a loss of 2 cents per share. Net product revenues for 2025 are expected to be in the range of $2.05-$2.25 billion. Collaborations and royalties revenues are expected to be $650-$750 million. Adjusted R&D and SG&A expenses are anticipated to be $2.1-$2.2 billion.

Alnylam has submitted regulatory applications for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy. A final decision from the FDA is expected on March 23, 2025. Alnylam currently carries a Zacks Rank #2 (Buy).



Read more at Zacks Investment Research: Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y – February 14, 2025